Chiang et al. hypothesized that in situ expansion of tumor‐infiltrating T cells could be achieved with the administration of IO@FuDex3, which contains both anti‐PD‐L1 and anti‐CD3/anti‐CD8 antibodies, whereas IO@FuDex1 contains anti‐CD3/anti‐CD8 antibodies and IO@FuDex2 contains anti‐PD‐L1 antibodies.[85] Magnetic navigation successfully promoted tumor accumulation of IO@FuDex3, resulting in over 15% ID g−1 at 24 h postinjection, compared to 5% without a magnet or <10% for IO@FuDex with a magnet. Here, CD8A is linked to neoplasm.